Main container

Targeting the intratumoral microbiota to reverse therapeutic resistance in lethal prostate cancers - Studio del microbiota intratumorale nelle metastasi ossee da carcinoma prostatici letali per identificare nuovi bersagli terapeutici e invertire la resist

Title
Targeting the intratumoral microbiota to reverse therapeutic resistance in lethal prostate cancers - Studio del microbiota intratumorale nelle metastasi ossee da carcinoma prostatici letali per identificare nuovi bersagli terapeutici e invertire la resist
Code
PROCBIOME
Type
Sperimentale
Start Year
2024
Status
In Corso

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Clinical Trial
A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
Read more
Clinical Trial
Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors
Read more
Content updated
31/07/2024 17:10